The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia

Bakhtawar Farooq, Rafay-Ur-Rehman Cheema, Zahid Habib Qureshi, Nabeela Yasmeen, Ejaz Hussain Sahu


Objective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treating diabetic dyslipidemia.
Study Design: Comparative cross-sectional study.
Place and Duration of Study: The study was conducted at the Department of Biochemistry, Nishtar Medical University and Hospital Multan, Pakistan over 12 months from January 2021 to January 2022.
Methods: Following a 4-week run-in phase, sixty newly diagnosed patients with a previous diagnosis of diabetes and dyslipidemia were included. Eligible participants were aged 18-65 years, with fasting triglyceride (TG) levels >200–400 mg/dL and documented type 2 diabetes mellitus (T2DM). Following baseline assessments, participants were randomised into two treatment groups: Saroglitazar 4 mg with 10 mg of Atorvastatin and Fenofibrate 200 mg with 10 mg of Atorvastatin. Lipid profiles, fasting blood glucose (FBG), and HbA1c were evaluated at baseline and after 12 weeks. Statistical analysis was conducted using appropriate tests with p< 0.05, which is considered significant.
Results: The study enrolled 60 participants, with comparable baseline characteristics between groups. While both treatments showed similar effects on lipid profiles, Saroglitazar showed exceptional effectiveness in lowering HbA1c and FBG levels compared to Fenofibrate. No significant differences in adverse effects were observed.
Conclusion: Saroglitazar may offer advantages in managing diabetic dyslipidemia and improving glycemic control compared to Fenofibrate in a larger sample size. More investigation is necessary to confirm these findings and evaluate long-term safety and efficacy.

Keywords: Atorvastatin, Diabetes Mellitus, Dyslipidemias, Fenofibrate, Triglyceride.

How to cite this: Farooq B, Cheema RR, Qureshi ZH, Yasmeen N, Sahu EH. The Effectiveness and Safety of Fenofibrate and Saroglitazar in The Treatment of Diabetic Dyslipidemia. Life and Science. 2024; 5(2): 266-272. doi:

Read PDF